ERBB2 and breast cancer: Studies have found that in patients with TNBC and HER2-positive breast cancer treated with trastuzumab, the decrease in DFS and OS was significant when adjuvant therapy was delayed for more than 60 days but not in HR-positive and HER2-negative breast cancer patients 40, 41.